🔴 Nasus Pharma is trading 5% down in pre-market after first-half loss widened

Nasus Pharma is trading 5.21% down now at $3.46 after investors reacted to its August 17 first-half results and business update.

• Reported a $5.94 million net loss, up from $1.25 million.
• Cash, cash equivalents, and short-term deposits totaled $11.9 million.
• Advancing NS002 toward a pivotal study, while increased development spending and an approximately ten-month cash runway remain concerns.